21st Annual Superbugs & Superdrugs Conference

21st Annual Superbugs & Superdrugs Conference is organized by SMi Group Ltd and will be held from Mar 18 - 19, 2019 at Holiday Inn Kensington Forum, London, England, United Kingdom.

As the global threat of antimicrobial resistance continues to grow, the advances of modern medicines are at risk of being lost. Failure to act quickly means the spread of antibiotic-resistant bacteria could lead to increased mortality from normally minor injuries and benign infections.

SMi’s highly anticipated Superbugs & Superdrugs conference is set to return to London, UK for its 21st year running, on the 18th & 19th March 2019. This year’s event aims to provide valuable insights and key updates on the latest developments within the scientific communities, as well as the processes and strategies pharmaceuticals use to develop novel therapeutics that utilise alternative mechanisms to treat multi-drug resistant infections. 

The two-day conference will also host a diverse gathering of policy makers and economists, in addition to big pharmas and biotechs, who will discuss incentives, partnerships, regulations and new policies. Industry experts and scientific pioneers are set to present on their research advances and clinical data, as well as alternatives to antibiotics, such as monoclonal antibodies and antimicrobial peptides.

Join us in London next year to explore the challenges and solutions to the growing threat of antibiotic resistance, as well as take part in interactive roundtable discussions with leading organisations. Attendees will also have the exclusive opportunity of networking with an unrivalled gathering of senior experts from Chemical Biology Ventures, University of Oxford, MedImmune, HPRA, GARDP, DNDi, Bioharmony Therapeutics, and many more.

Benefits of Attending :
By attending our 21st annual Superbugs & Superdrugs event, you will benefit from the knowledge delivered through range of thought-provoking presentations, by experts at the forefront of the field; receiving the opportunity to interact with and exchange ideas with decision makers from all of the different facets of the industry - from research to commercial providers and regulatory bodies.
• Analyze the current status of antimicrobial resistance with industry-led insight into current strategies to tackle AMR
• Hear about novel immunotherapeutics to target Gram-negative bacterial infections
• Learn about strategies to combat β-lactamases
• Evaluate the development of precision antibiotics: agents designed to meet the demands of stewardship
• Explore the role of plasmids in the evolution of antimicrobial resistance

Who should attend :
• Research and Development Directors
• Chief Scientific Officers
• Chief Medical Officers
• Heads of Global Antimicrobial Stewardship
• Pharmaceutical Research & Development/ Drug Discovery Scientists

Additional details will be posted as soon as they are available.